AIM ImmunoTech Inc. 8-K

What Happened

• AIM ImmunoTech Inc. (AIM) filed an 8-K on February 5, 2026 furnishing three items: a February 2026 corporate presentation (Exhibit 99.1), a Year‑End interim clinical progress update on DURIPANC (Exhibit 99.2), and a press release (Exhibit 99.3).
• The DURIPANC update covers a Phase I/II open‑label study testing durvalumab (Imfinzi) in combination with rintatolimod (Ampligen®) in pancreatic cancer patients with stable disease following FOLFIRINOX chemotherapy. The filing notes the update is interim and the exhibits are “furnished” (not “filed”) under the Exchange Act.
• The filing includes AIM’s customary forward‑looking statement caution: results are preliminary, additional testing will be required, and no assurance is given that trials will be successful or yield favorable data.

Key Details

• Filing date: February 5, 2026 (Form 8‑K, Items 7.01 and 8.01).
• Study: Phase I/II open‑label DURIPANC trial of durvalumab + rintatolimod in post‑FOLFIRINOX pancreatic cancer patients.
• Exhibits furnished: 99.1 (Feb 2026 corporate presentation), 99.2 (DURIPANC year‑end interim clinical progress update), 99.3 (Feb 5, 2026 press release).
• Disclosure status: Materials are “furnished” (not “filed”) and include standard forward‑looking statement disclaimers.

Why It Matters

• For investors, clinical updates on DURIPANC are material because trial progress or interim data can influence AIM’s development timeline and perceived value of Ampligen as a potential oncology therapy.
• The update does not provide definitive efficacy or regulatory outcomes; AIM emphasizes that further clinical testing and approvals are required. Investors should consult AIM’s recent 10‑K/10‑Q risk disclosures for context and monitor subsequent filings for detailed trial data.